Form 4: Quest Diagnostics Executive Reports Stock Transactions

Catherine T. Doherty, EVP at Quest Diagnostics, reports acquisition and disposition of company stock related to a performance share award.

Summary

• Catherine T. Doherty, an Executive Vice President at Quest Diagnostics, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On February 23, 2024, Doherty acquired 9,314 shares of common stock at a price of $125.02 per share as settlement of a performance share award.
• On the same day, she disposed of 3,757 shares at $125.02 per share to cover tax withholding obligations related to the award.
• Following these transactions, Doherty directly owns 76,357 shares of Quest Diagnostics common stock.
• She also indirectly owns 4,349 shares through the company's 401(k) and Supplemental Deferred Compensation Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation. There is no indication of unusual or concerning activity.

Positives

• The acquisition of shares through a performance share award suggests that Doherty has met certain performance criteria, which could be viewed positively.

Negatives

• The disposition of shares to cover tax obligations, while standard, reduces Doherty's overall holdings in the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates transactions related to executive compensation and tax obligations, which are common occurrences.

Comparison to Industry Standards

• Executive compensation packages often include stock options and performance-based awards, aligning management's interests with those of shareholders.
• The tax treatment of stock awards is standard practice, with companies typically withholding shares to cover tax obligations.
• Comparing Doherty's holdings and transactions to those of executives at similar diagnostic companies (e.g., Laboratory Corporation of America, Bio-Reference Laboratories) could provide further context, but that data is not available in this document.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The filing provides transparency to shareholders regarding executive stock ownership.

Key Dates